Skip to main content

Advertisement

SpringerLink
Log in

miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2)

  • Research Article
  • Published:
Tumor Biology

Abstract

MicroRNAs are short regulatory RNAs that play crucial roles in cancer development and progression. MicroRNA-646 (miR-646) is downregulated in many human cancers, and increasing evidence indicates that it functions as a tumor suppressor. However, the role of miR-646 in osteosarcoma remains unclear. Expression levels of miR-646 in osteosarcoma cell lines and patient tissues were evaluated by quantitative real-time PCR (qRT-PCR), and the clinicopathological significance of the resultant data was later analyzed. Next, we investigated the role of miR-646 to determine its potential roles on osteosarcoma cell proliferation, migration, and invasion in vitro. A luciferase reporter assay was conducted to confirm the target gene of miR-646, and the results were validated in the osteosarcoma cell line. In this study, we found that miR-646 was downregulated in osteosarcoma cell lines and osteosarcoma tissues compared with normal osteoblast cell line NHOst and paired adjacent nontumor tissue. We found that a lower expression of miR-646 was associated with metastasis. In osteosarcoma cells, overexpression of miR-646 inhibited cell proliferation, migration, and invasion. In contrast, downregulation of miR-646 expression promoted osteosarcoma cell proliferation, migration, and invasion. Next, we identified that the FGF2 gene is a novel direct target of miR-646 in osteosarcoma cells. Moreover, enforced expression of FGF2 partially reversed the inhibition of cell proliferation, migration, and invasion that was caused by miR-646. Our study demonstrated that miR-646 might be a tumor suppressor in osteosarcoma via the regulation of FGF2, which provided a potential prognostic biomarker and therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma[M]//pediatric and adolescent osteosarcoma. US: Springer; 2010. p. 3–13.

    Google Scholar 

  2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19(6):1123–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yates LA, Norbury CJ, Gilbert RJC. The long and short of microRNA. Cell. 2013;153(3):516–9.

    Article  CAS  PubMed  Google Scholar 

  5. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chow TF, Mankaruos M, Scorilas A, et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol. 2010;183(2):743–51.

    Article  CAS  PubMed  Google Scholar 

  8. Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in human cancer[M]//microRNA cancer regulation. Netherlands: Springer; 2013. p. 1–20.

    Google Scholar 

  9. Zhou Y, Huang Z, Wu S, et al. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res: CR. 2014;33(1):12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Huang J, Gao K, Lin J, et al. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumor Biol. 2014;35(2):1095–100.

    Article  CAS  Google Scholar 

  11. Zhao G, Cai C, Yang T, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8(1):e53906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Finnerty JR, Wang WX, Hébert SS, et al. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010;402(3):491–509.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang WT, Zhao YN, Yan JX, et al. Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery. J Hematol Oncol. 2014;7(1):6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Li W, Liu M, Feng Y, et al. Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1). Br J Cancer, 2014.

  15. Zhang H, Zhang Y, Duan HO, et al. TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer. 2008;123(4):810–6.

    Article  CAS  PubMed  Google Scholar 

  16. Paterson EL, Kazenwadel J, Bert AG, et al. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15(2):180–IN22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Qi L, Bart J, Tan LP, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Cronauer MV, Schulz WA, Seifert HH, et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol. 2003;43(3):309–19.

    Article  CAS  PubMed  Google Scholar 

  20. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29.

    Article  CAS  PubMed  Google Scholar 

  21. Kuhn H, Köpff C, Konrad J, et al. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer. 2004;44(2):167–74.

    Article  PubMed  Google Scholar 

  22. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999;5(5):1063–71.

    CAS  PubMed  Google Scholar 

  23. Polnaszek N, Kwabi-Addo B, Peterson LE, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003;63(18):5754–60.

    CAS  PubMed  Google Scholar 

  24. Li D, Wei X, Xie K, et al. A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer, 2014.

  25. Zhou B, Ma R, Si W, et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett. 2013;333(2):159–69.

    Article  CAS  PubMed  Google Scholar 

  26. Ren T, Qing Y, Dai N, et al. Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci. 2014;105(2):186–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Orthopedics, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui, 453100, China

    Xiao-hui Sun, Xiao-lin Geng, Jun Zhang & Chao Zhang

Authors
  1. Xiao-hui Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-lin Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-hui Sun.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, Xh., Geng, Xl., Zhang, J. et al. miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2). Tumor Biol. 36, 2127–2134 (2015). https://doi.org/10.1007/s13277-014-2822-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2822-z

Keywords

Search

Navigation